PAH is a complex, progressive disease where high blood pressure in the lungs eventually causes right-sided heart failure.^1,2 In 1995, parenteral prostacyclin therapy was the only PAH-specific therapy available.³ Now there are >12 approved therapies treating 4 different pathways.² Further advances in formulations and administration routes—including nebulizers and small, handheld inhalers, oral pills, and parenteral subcutaneous and intravenous pumps⁠—⁠give you even more options for tailored management of your patients with PAH.^2,4-6

Improving risk status is key to improving outcomes⁴

2022 ESC/ERS Treatment Guidelines, with support from the 2024 WSPH Proceedings, help you navigate care for patients with PAH, including aligning risk assessment and therapy choices throughout the course of PAH. Conducting PAH risk assessment helps to understand your patient's disease status and set objective treatment goals at diagnosis. Proactive monitoring that includes frequent risk assessment and timely treatment plan adjustments are critical to improving outcomes and achieving treatment goals for your patients.⁴

PAH Initiative is here to support you and your patients

The PAH Initiative is a resource designed to support your goals of helping patients feel better and improve their prognosis.

According to the 2022 ESC/ERS Treatment Guidelines, achieving these goals should involve:

• Setting clear treatment goals related to improved patient prognosis, including⁴:
  • Achieving near-normalization of the right heart
  • Aiming for low-risk status
• Using risk scores at diagnosis of PAH to determine initial treatment plan
• Repeating risk assessment as often as every 3 months afterward to determine when treatment plan should be adjusted
  • For patients not at low risk at follow-up, treatment plan adjustment is recommended
• Escalating treatment or changing therapy as recommended by evidence-based guidelines to achieve treatment goals